Engineering next-generation CAR-NK cells for hematological malignancies: genome editing, synthetic biology, and precision immunotherapy
Chimeric antigen receptor (CAR)-based immunotherapy has transformed cancer treatment by enabling engineered immune cells to selectively recognize and eliminate malignant targets, with CAR-T cells establishing the first major clinical success in this field. However, severe associated toxicities, logistical complexitie...